Orexigen Therapeutics Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced that Michael Narachi, president and CEO, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a two-year term.
PhRMA represents biopharmaceutical research and biotechnology companies that are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.
"PhRMA represents an industry dedicated to the noblest of missions: Improving the health of patients all over the world," Narachi said. "I'm honored to join the board of PhRMA, and I'm looking forward to being a part of an organization whose mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients."
Narachi has served as Orexigen's president and CEO and a member of Orexigen's board of directors since March 2009.
Before joining Orexigen, Narachi served as chairman, CEO and president of Ren Pharmaceuticals Inc., a private biotechnology company, and chairman of the board of directors of Naryx Pharma Inc., a private pharmaceutical company. In 2004, Narachi left Amgen Inc., where he served as an officer and vice president and as general manager of Amgen's anemia business.
Narachi also serves as a member of the board of directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals Inc. (Nasdaq: AMAG), a pharmaceutical company.
3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037